|Dr. Peter Wrighton-Smith||CEO & Exec. Director||1.11M||N/A||1974|
|Mr. Matthew T.E. McLaughlin||Chief Financial Officer||527.45k||N/A||1977|
|Ms. Janet Louise Kidd||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Dr. Peter Edwardson||Sr. VP & Head of Blood Screening||N/A||N/A||1962|
|Mr. Jeff R. Schroeder||Pres, Strategic Accounts||N/A||N/A||1961|
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States, Europe, Asia, and internationally. The company develops its products using its T-SPOT technology platform that measures marker-specific cellular (T cells) responses at a single cell level and inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis; and reagents and methods to purify white blood cells for use in immunology assays. In addition, the company offers T-SPOT.CMV, an immune monitoring test for cytomegalovirus (CMV) for the quantification of effector T cells that respond to stimulation by antigens specific for CMV, as well as for the monitoring of CMV-seropositive responses in transplant recipients at various time-points post-transplantation applications. It serves independent laboratories, hospital systems, and public and private institutions. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
Oxford Immunotec Global PLC’s ISS Governance QualityScore as of December 5, 2019 is 6. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 5; Compensation: 8.